Trial Profile
An Open-Label, Multicenter, Dose-Escalation and Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KN046 Monotherapy in Subjects With Advanced Solid Tumors and Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Erfonrilimab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Alphamab Biopharmaceuticals
- 24 Oct 2023 Results of efficacy and safety outcomes of KN046 in this population from KN046-CHN-001 and Cohort C of KN046-201, presented at the 48th European Society for Medical Oncology Congress
- 08 Jun 2023 Status changed from recruiting to completed.
- 14 Jan 2019 Status changed from not yet recruiting to recruiting.